Biotech & Pharma

Compass, with Phase 3 hits, ready to take psilocybin to the FDA

24 sec read9 views0 listens

Compass is preparing to meet with the FDA to discuss a rolling approval application for its synthetic psilocybin compound, COMP360, aiming to make it the first classic psychedelic approved in the U.S. market. This development could significantly impact mental health treatment options, offering new avenues for content creators to explore and educate about psychedelic therapies.

Read the full article at BioPharma Dive

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Cybersecurity9 hours ago29 sec read

Waiting for care: Why Canadians' healthcare expectations are colliding with reality

A new survey reveals that nearly half of Canadians waited longer than a week for their most recent routine medical appointment, despite expecting quicker access. This growing gap between expectations and reality highlights significant challenges in t...

Ali Nemati

Legal & Policy9 hours ago25 sec read

Animal Justice Calls on Fisheries Minister to Investigate Beluga's Death, Demands Pause on Marineland Transports

Animal Justice is urging the federal Fisheries Minister to investigate the death of a beluga whale named Peekachu who died shortly after being transported from Marineland to Shedd Aquarium. The organization demands a halt to further transports until ...

Ali Nemati

Real Estate & Home10 hours ago25 sec read

'Spend one night here': Anger explodes over new Western Sydney airport night flights

Residents near the new 24/7 Western Sydney International Airport are facing severe sleep disruptions due to frequent nighttime cargo flights, leading to health issues and potential relocation. This development highlights the need for effective noise ...

Ali Nemati